Related Experiment Video

Updated: Jun 5, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.8K

Iron deficiency and heart failure with preserved ejection fraction

Tetyana M Ternushchak1, Marianna I Tovt-Korshynska1, Snizhana V Feysa1

  • 1UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE.

Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|December 11, 2024
PubMed

Insights

Iron deficiency (ID) is common in heart failure with preserved ejection fraction (HFpEF), affecting 63% of patients. This comorbidity significantly reduces functional capacity and quality of life.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Clinical Research

Background:

  • Heart failure with preserved ejection fraction (HFpEF) is a complex condition with multiple comorbidities.
  • Iron deficiency (ID) is increasingly recognized as a significant comorbidity in heart failure patients.

Purpose of the Study:

  • To determine the prevalence of iron deficiency (ID) in patients diagnosed with HFpEF.
  • To investigate the relationship between ID and functional capacity in HFpEF patients.
  • To assess the impact of ID on the quality of life in individuals with HFpEF.

Main Methods:

  • A cohort of 121 consecutive outpatients newly diagnosed with HFpEF were analyzed.
  • Patients were evaluated for iron status using serum ferritin and transferrin saturation (TSAT).
  • Functional capacity was assessed using the 6-minute walk test (6MWT), and quality of life was measured with the Minnesota Living with Heart Failure Questionnaire.

Main Results:

  • Iron deficiency (ID) was prevalent in 63% of the HFpEF patients studied.
  • Patients with ID exhibited more severe HF symptoms, higher NT-proBNP and hs CRP levels, and poorer diastolic function.
  • HFpEF patients with ID demonstrated significantly reduced functional capacity and lower quality of life scores.

Conclusions:

  • Iron deficiency (ID) is a highly prevalent comorbidity in patients with HFpEF.
  • The presence of ID is strongly associated with impaired functional capacity and diminished quality of life in HFpEF.
  • Addressing ID may be crucial for improving clinical outcomes in HFpEF management.
Abstract

Keywords:
heart failure with preserved ejection fractioniron deficiency

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.4K

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
340
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
2
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
517